| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/10/2002 | EP1195161A2 Anti-IgE vaccines |
| 04/10/2002 | EP1194555A1 Methods for making apo-2 ligand using divalent metal ions |
| 04/10/2002 | EP1194529A1 Composition for the preservation of infectious recombinant adenoviruses |
| 04/10/2002 | EP1194444A2 Labeled neurotensin derivatives with improved resistance to enzymatic degradation |
| 04/10/2002 | EP1194174A2 Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood |
| 04/10/2002 | EP1194173A1 X-ray guided drug delivery |
| 04/10/2002 | EP1194171A2 Nitric oxide-producing hydrogel materials |
| 04/10/2002 | EP1194170A1 Growth hormone formulations |
| 04/10/2002 | EP1194168A2 Methods and products for manipulating uncoupling protein expression |
| 04/10/2002 | EP1194167A1 Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| 04/10/2002 | EP1194166A2 Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
| 04/10/2002 | EP1194161A1 Stable factor viii compositions |
| 04/10/2002 | EP1194154A1 Use of propionic bacteria for producing propionic acid and/or propionates in the colon |
| 04/10/2002 | EP1194153A1 Taste masked pharmaceutical liquid formulations |
| 04/10/2002 | EP1194145A2 Stable xylometazoline and oxymetazoline solution |
| 04/10/2002 | EP1194140A1 Pharmaceutical composition containing fenofibrate and preparation method |
| 04/10/2002 | EP1194136A1 Non-solid composition for local application |
| 04/10/2002 | EP1194133A2 Multilayered film containing an active substance and made of cross-linked hydrophilic polymers |
| 04/10/2002 | EP1194132A2 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| 04/10/2002 | EP1194131A1 Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| 04/10/2002 | EP1194130A1 Improvements in and relating to delivery capsules |
| 04/10/2002 | EP1194129A1 Self-emulsifying systems containing anticancer medicament |
| 04/10/2002 | EP1194126A1 Dry powder compositions |
| 04/10/2002 | EP1194125A1 Method for making granules with masked taste and instant release of the active particle |
| 04/10/2002 | EP1194123A2 Method for controlled production of ultrafine microparticles and nanoparticles |
| 04/10/2002 | EP1194122A1 Methods for preparation of lipid-encapsulated therapeutic agents |
| 04/10/2002 | EP1194121A1 Steroid solution aerosol products with enhanced chemical stability |
| 04/10/2002 | EP1194120A1 Clear oil-containing pharmaceutical compositions |
| 04/10/2002 | EP1194119A1 Controlled release of therapeutics by in-situ entrapment by matrix cross-linking |
| 04/10/2002 | EP1194113A2 Preservatives for perishable preparations, in particular for cosmetic and pharmaceutical preparations |
| 04/10/2002 | EP1194109A1 Topical formulations comprising skin penetration agents and the use thereof |
| 04/10/2002 | EP1194044A1 Novel pharmaceutical or dietetic mushroom-based compositions |
| 04/10/2002 | EP1089719B1 Transdermal therapeutic system containing hormones and crystallization inhibitors |
| 04/10/2002 | EP1051159B1 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis |
| 04/10/2002 | EP0930885B1 The use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus |
| 04/10/2002 | EP0918510B1 Bioadhesive complexes of polycarbophil and azole antifungal or antiprotozoal drugs |
| 04/10/2002 | EP0861067B1 Unit galenical form for local hormonotherapy of vaginal dryness |
| 04/10/2002 | EP0819009B1 Ovulation triggering drugs comprising luteinising hormone |
| 04/10/2002 | EP0807434B1 Anti-inflammatory eyedrops |
| 04/10/2002 | EP0788383B1 Modulation of cell proliferation and wound healing |
| 04/10/2002 | EP0764032B1 Stable gel formulation for topical treatment of skin conditions |
| 04/10/2002 | EP0675727B1 Glycolipid enzyme-polymer conjugates |
| 04/10/2002 | EP0607206B1 Composition for inserting nucleic acid complexes into higher eucaryotic cells |
| 04/10/2002 | CN1344287A Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| 04/10/2002 | CN1344169A Glycoconjugates obtained from i(candide Utilis) cells and i(Ricinus)i(communis) seeds |
| 04/10/2002 | CN1344166A Use of enterobacterium protein ompA associated with antigen for generating antiviral, antiparasitic or antitumoral cytotoxic response |
| 04/10/2002 | CN1344165A Antiviral agent in form of nose drops |
| 04/10/2002 | CN1344163A Stabilized oral pharmaceutical compsn. contg. iodide and iodate and method |
| 04/10/2002 | CN1344155A Transnasal transport/immunisation with highly adaptable carriers |
| 04/10/2002 | CN1344154A Absorbent article compsn. and method of use for sequestering skin irritants |
| 04/10/2002 | CN1344153A Facial tissue compsn. and method of use for sequestration of nasal secretion skin irritants |
| 04/10/2002 | CN1343520A Method for controlling slow release speed of medicine by porous nano carrier material |
| 04/10/2002 | CN1343487A Increasing agent for fregrance spreading rate and lasting property and increasing method thereof |
| 04/10/2002 | CN1082373C Medicines and drinking products for prevention and treatment gastrointestinal diseases |
| 04/10/2002 | CN1082369C Formulations contg. carotenoids and procarotenoids combined with polyphenols |
| 04/10/2002 | CN1082368C HCG liquid formulations |
| 04/09/2002 | US6369260 Process for the preparation of a pharmacologically active chemical combination |
| 04/09/2002 | US6369206 Metal organothiol particles |
| 04/09/2002 | US6369204 Receptor known to be expressed in large amounts on the surface of osteoclasts and associated with bone resorption; use treating osteoporosis and/or in the inhibition of tumor cell growth |
| 04/09/2002 | US6369115 Stabilized powder formulations |
| 04/09/2002 | US6369087 Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| 04/09/2002 | US6369062 Sustained release ranolazine formulations |
| 04/09/2002 | US6369037 Impregnated in a dextran-methacrylate biodegradable hydrogel; higher cumulative release in acid ph (e.g., the stomach); prepared without chemical crosslinker and heat; oral administration or an implant |
| 04/09/2002 | US6368853 A nucleic acid encoding a polypeptide ligand; tyrosine kinase containing immunoglobulin and epidermal growth factor homolog domains; therapy and diagnosis for angiogenesis in wound healing, inflammation or tumors |
| 04/09/2002 | US6368788 Method of treating complications in immunodepressed states resulting from HIV infection |
| 04/09/2002 | US6368635 Gastrointestinal mucosa-adherent matrixes pharmaceutical preparations and a coating composition |
| 04/09/2002 | US6368632 Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| 04/09/2002 | US6368631 Fine grain carriers and medicinal composition prepared with the use of the same |
| 04/09/2002 | US6368629 Drug with protective coatings |
| 04/09/2002 | US6368627 Compositions |
| 04/09/2002 | US6368626 Semipermeable wall |
| 04/09/2002 | US6368625 Dosage forms |
| 04/09/2002 | US6368618 Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs |
| 04/09/2002 | US6368616 Aqueous suspension for nasal administration of loteprednol |
| 04/09/2002 | US6368598 Administering complex of polyamine carrier, drug and connector |
| 04/09/2002 | US6368596 Monoclonal antibody complex; anticancer agent |
| 04/09/2002 | US6368595 Forming a formulation comprising protease enzyme and polyvinyl alcohol film forming agent, topically applying the formulation, incubating to form a film incorporating enzyme, removing the film incorporating the enzyme from the site |
| 04/09/2002 | US6368586 Surface treatment; exposure of polymer to metal compound; sustained drug release |
| 04/09/2002 | CA2249744C Oral peptide pharmaceutical products |
| 04/09/2002 | CA2141691C Solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof |
| 04/09/2002 | CA2083271C Fibrin binding domain polypeptides and uses and methods of producing same |
| 04/04/2002 | WO2002027317A2 Conjugates of defined stoichiometry |
| 04/04/2002 | WO2002026867A2 Dendrimeric support or carrier macromolecule |
| 04/04/2002 | WO2002026845A1 Aqueous polymer dispersion |
| 04/04/2002 | WO2002026822A2 Pumpcn compositions and uses thereof |
| 04/04/2002 | WO2002026782A2 Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| 04/04/2002 | WO2002026779A2 A fibrin/fibrinogen-binding conjugate |
| 04/04/2002 | WO2002026757A2 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 04/04/2002 | WO2002026716A2 Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections |
| 04/04/2002 | WO2002026372A2 Instant water dissolvable encapsulate and process |
| 04/04/2002 | WO2002026324A2 Tocol-based compositions containing amiodarone |
| 04/04/2002 | WO2002026277A2 Stabilized hydrogen peroxide solutions |
| 04/04/2002 | WO2002026265A2 Pegylated interleukin-10 |
| 04/04/2002 | WO2002026262A2 Compositions for reducing side effects in chemotherapeutic treatments |
| 04/04/2002 | WO2002026241A1 Polymeric micelle containing cisplatin enclosed therein and use thereof |
| 04/04/2002 | WO2002026237A1 Liquid prednisolone sodium phosphate preparation |
| 04/04/2002 | WO2002026220A2 Taxoid conjugates as antimitotic and antitumor agents |
| 04/04/2002 | WO2002026217A2 Composition for the transdermal delivery of fentanyl |
| 04/04/2002 | WO2002026215A2 Thermogelling biodegradable aqueous polymer solution |
| 04/04/2002 | WO2002026214A1 Ion-strength independent sustained release pharmaceutical formulation |